Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment. The active ingredients produce substantially greater weight loss than any other drugs on the market. I’d venture a guess that some investors assume that the best returns have already been had. However, there’s lots of evidence suggesting otherwise. Global obesity spending is ...